Newborn SMA Screening: Heel Prick Test to Launch in England
England is preparing to introduce heel prick SMA testing for every newborn baby, a long-awaited change welcomed as a victory by campaigners including singer Jesy Nelson. The screening will identify Spinal Muscular Atrophy within days of birth, opening the door to life-changing early treatment.
## Background
England is preparing to roll out routine heel prick SMA testing for every newborn baby, marking a major milestone in the fight against Spinal Muscular Atrophy. The condition is a leading genetic cause of death in infants, and early detection has long been demanded by families and patient advocates.
## Why the Screening Matters
Spinal Muscular Atrophy attacks the motor neurons that control muscle movement, and the most severe form can leave babies unable to breathe, swallow, or move within months. Until now, most cases were diagnosed only after symptoms appeared, by which point irreversible damage had often already occurred. New treatments, including gene therapies, have transformed outcomes, but only when given early, making newborn SMA screening a race against time.
## A Mother's Campaign
Former Little Mix star Jesy Nelson has been one of the most vocal champions of expanded newborn screening in England. After her own son was diagnosed with the condition, she has used her platform to push the NHS to add SMA to the standard heel prick test. She described the government's confirmation of the rollout as a "victory" for every family who could now receive a diagnosis before symptoms take hold.
## How the Test Works
The heel prick test, formally known as the newborn blood spot screening, already checks for several rare but serious conditions within the first days of life. A small blood sample is taken from the baby's heel and analysed in a laboratory. Adding SMA to this panel is a relatively low-cost upgrade that health officials say could save dozens of lives every year across England.
## What Happens Next
NHS England is expected to begin phasing in the expanded screening across maternity units, with full coverage targeted in the near future. Families who receive a positive result will be referred immediately to specialist neuromuscular teams, where treatment options including gene-replacement therapies can be discussed. Campaigners hope the move will pressure other UK nations to follow suit and bring the country in line with global screening standards.
Topics
